August 15, 2016 / 8:05 AM / 3 years ago

Delaware court backs UCB drug patent, shares jump

(Reuters) - A ruling by the Delaware District Court in the United States upholding the validity of UCB’s patent for epilepsy drug Vimpat sent shares in the Belgian pharmaceutical firm up more than 7 percent on Monday.

Sales of the drug totaled 679 million euros ($759 million) last year, of which about three quarters were in the United States.

Reporting by Wout Vergauwen; editing by Jason Neely

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below